Pillsolution Exim Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Revenue 1114.88%
(FY 2020)
- Profit 30.70%
(FY 2020)
- Ebitda -343.99%
(FY 2020)
- Net Worth 62.54%
(FY 2020)
- Total Assets 230.88%
(FY 2020)
About Pillsolution Exim
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Mandlekar and Amita Mandlekar serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC287641
- Company No.
287641
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Nov 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Pillsolution Exim Private Limited offer?
Pillsolution Exim Private Limited offers a wide range of products and services, including Animal Medicines & Health Care, Anthelmintics, Nutraceuticals & Dietary Supplements, Weight Loss Supplement, Common Disease Medicines, Pharmaceutical Capsules, Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup.
Who are the key members and board of directors at Pillsolution Exim?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Mandlekar  | Director | 15-Nov-2016 | Current |
| Amita Mandlekar | Director | 13-Oct-2017 | Current |
Financial Performance of Pillsolution Exim.
Pillsolution Exim Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1114.88% increase. The company also saw a substantial improvement in profitability, with a 30.7% increase in profit. The company's net worth Soared by an impressive increase of 62.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pillsolution Exim?
In 2017, Pillsolution Exim had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Accugenic Lifesciences Private LimitedActive 4 years 6 monthsRahul Mandlekar and Amita Mandlekar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pillsolution Exim?
Unlock and access historical data on people associated with Pillsolution Exim, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pillsolution Exim, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pillsolution Exim's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
